Monitor SAFEGUARD enrollment completion (expected Q4 2026) and topline data in 2H 2027 as the primary catalysts. The Fast Track designation may accelerate regulatory interactions but does not guarantee approval. Cash runway through 2028 reduces near-term dilution risk but the widening net loss underscores the pre-revenue stage.
Drug in focus
SABS drug pipeline →SAB-142
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2b (registrational)
- Time to market
- Potentially 2028-2029 if Phase 2b succeeds, given the registrational trial topline reads out in 2H 2027 and accelerated approval is possible via the C-peptide surrogate endpoint pathway
- Next catalyst
- None dated
What to watchSAB-142 is early-stage but has strong institutional validation and ample cash runway through 2028. The next major catalyst (Phase 2b topline data) is still over a year away, so near-term moves will be driven by enrollment milestones, conference data presentations, and progress on the PRISE-hATG study. The stock carries elevated short interest (~56-61% short ratio), so positive enrollment updates could trigger short squeezes. For investors, this is a pre-revenue binary bet with no near-term FDA decision, sizing accordingly is key.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $2.94entry
- T+1 · 11d ago +3.06%α +2.75% · $3.03
- T+5 · 5d ago +4.76%α +1.47% · $3.08
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics reported a Q3 2026 net loss of $22.3M vs net income of $45.4M a year ago, driven by higher R&D and G&A costs for its lead T1D candidate SAB-142. The registrational SAFEGUARD study is on track for full enrollment in Q4 2026 with topline data expected in 2H 2027, and the company received FDA Fast Track designation for SAB-142 in October 2026. Cash of $205.3M provides runway through 2028, but the net loss widened significantly from a year-ago period that included a $58.1M non-cash gain.
Key Facts
- Net loss of $22.3M for Q3 2026 vs net income of $45.4M in Q3 2025 (prior year included $58.1M non-cash gain from warrant liability revaluation)
- R&D expenses $18.1M (Q3 2026) vs $9.0M (Q3 2025), driven by clinical trial costs and headcount for SAB-142
- G&A expenses $7.8M (Q3 2026) vs $3.7M (Q3 2025), driven by personnel costs including stock-based compensation
- Cash, cash equivalents and investment securities $205.3M at September 30, 2026, providing operational runway through 2028
- SAFEGUARD Phase 2b study adult and adolescent cohorts fully enrolled; pediatric cohort actively enrolling; full enrollment on track for Q4 2026
- Topline data from SAFEGUARD expected in second half of 2027
- FDA granted Fast Track designation for SAB-142 in new-onset Stage 3 T1D in October 2026
- Phase 3 PRISE-hATG study expects to dose first patient in Q4 2026
- Consensus EPS estimate was $-0.27; actual EPS not explicitly stated in the release (net loss $22.3M on weighted shares not given)
Financial Impact
Net loss of $22.3M in Q3 2026 vs net income of $45.4M in Q3 2025; cash burn rate implied by $205.3M cash position and current spending levels provides runway through 2028
Risk Factors
- Clinical-stage company with no approved products or revenue; net loss widening as R&D spending increases
- SAFEGUARD trial results are binary and not expected until 2H 2027; any enrollment delays or safety signals could pressure the stock
- Fast Track designation does not guarantee faster review or approval
- Stock-based compensation ($7.5M combined in Q3 2026) adds to cash burn and dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396298 |
Track record
15 reports on SABS
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers